ID   NCC-ES2-C1
AC   CVCL_B7PH
DR   Wikidata; Q112930162
RX   PubMed=35441357;
WW   https://en.cellline.jp/product/ncc-es2-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: ~159 hours (PubMed=35441357).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=EWSR1 exon 7 fused to FLI1 exon 8 (PubMed=35441357).
CC   Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.
ST   Source(s): PubMed=35441357
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,10
ST   D16S539: 10
ST   D21S11: 28,30
ST   D5S818: 10,12
ST   D7S820: 10,12
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   17Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 30-01-24; Version: 5
//
RX   PubMed=35441357; DOI=10.1007/s13577-022-00701-9;
RA   Yoshimatsu Y., Noguchi R., Sin Y., Tsuchiya R., Ono T., Akiyama T.,
RA   Nakagawa R., Kamio S., Hirabayashi K., Ozawa I., Kikuta K., Kondo T.;
RT   "Establishment and characterization of a novel patient-derived Ewing
RT   sarcoma cell line, NCC-ES2-C1.";
RL   Hum. Cell 35:1262-1269(2022).
//